Obermeyer Wood Investment Counsel Lllp bought a new stake in shares of Quidel Corp. (NASDAQ:QDEL) during the third quarter, Holdings Channel reports. The fund bought 18,000 shares of the company’s stock, valued at approximately $398,000. Obermeyer Wood Investment Counsel Lllp owned about 0.06% of Quidel Corp. as of its most recent SEC filing.
A number of other hedge funds also recently made changes to their positions in QDEL. State of Wisconsin Investment Board bought a new stake in shares of Quidel Corp. during the third quarter valued at approximately $1,767,000. Wells Fargo & Company MN boosted its stake in shares of Quidel Corp. by 26.1% in the third quarter. Wells Fargo & Company MN now owns 13,544 shares of the company’s stock valued at $299,000 after buying an additional 2,800 shares during the last quarter. Capital Fund Management S.A. bought a new stake in shares of Quidel Corp. during the third quarter valued at approximately $384,000. Eagle Boston Investment Management Inc. boosted its stake in shares of Quidel Corp. by 0.8% in the third quarter. Eagle Boston Investment Management Inc. now owns 328,963 shares of the company’s stock valued at $7,266,000 after buying an additional 2,474 shares during the last quarter. Finally, Macquarie Group Ltd. boosted its stake in shares of Quidel Corp. by 27.7% in the second quarter. Macquarie Group Ltd. now owns 858,387 shares of the company’s stock valued at $15,331,000 after buying an additional 186,020 shares during the last quarter. Institutional investors and hedge funds own 92.75% of the company’s stock.
Quidel Corp. (NASDAQ:QDEL) opened at 23.37 on Friday. The company has a 50 day moving average price of $21.15 and a 200-day moving average price of $20.10. Quidel Corp. has a one year low of $13.21 and a one year high of $23.94. The company’s market capitalization is $762.87 million.
Quidel Corp. (NASDAQ:QDEL) last announced its quarterly earnings data on Wednesday, October 26th. The company reported $0.10 earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.02) by $0.12. The company had revenue of $49.30 million for the quarter, compared to analysts’ expectations of $50.88 million. Quidel Corp. had a negative return on equity of 0.81% and a negative net margin of 6.40%. Quidel Corp.’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same period last year, the firm posted ($0.05) EPS. Analysts expect that Quidel Corp. will post ($0.16) EPS for the current fiscal year.
Several analysts recently commented on the company. Zacks Investment Research upgraded Quidel Corp. from a “sell” rating to a “hold” rating in a report on Friday, November 4th. Canaccord Genuity set a $22.00 target price on Quidel Corp. and gave the company a “hold” rating in a report on Thursday, October 27th. One analyst has rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the company. Quidel Corp. presently has a consensus rating of “Hold” and a consensus target price of $21.58.
In related news, CEO Douglas C. Bryant sold 69,168 shares of the firm’s stock in a transaction dated Friday, September 30th. The stock was sold at an average price of $21.76, for a total transaction of $1,505,095.68. Following the transaction, the chief executive officer now directly owns 291,121 shares of the company’s stock, valued at approximately $6,334,792.96. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Douglas C. Bryant sold 2,832 shares of the firm’s stock in a transaction dated Tuesday, August 30th. The shares were sold at an average price of $22.00, for a total value of $62,304.00. Following the transaction, the chief executive officer now directly owns 276,843 shares in the company, valued at $6,090,546. The disclosure for this sale can be found here. Corporate insiders own 23.40% of the company’s stock.
About Quidel Corp.
Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. The Company’s diagnostic testing solutions primarily include applications in infectious diseases, women’s health and gastrointestinal diseases. It sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics and wellness screening centers.